Literature DB >> 8018843

Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease.

E K Perry1, V Haroutunian, K L Davis, R Levy, P Lantos, S Eagger, M Honavar, A Dean, M Griffiths, I G McKeith.   

Abstract

Activity of the enzyme which synthesizes acetylcholine, choline acetyltransferase, was estimated in the neocortex of three series of control and demented cases. Clinically demented cases were divided into those with the classical neuropathological features of Alzheimer's disease (numerous neocortical plaques and tangles) and those with Lewy bodies in the brain stem and cortex (together with plaques and variable neurofibrillary pathology). In the Lewy body cases neocortical choline acetyltransferase was consistently lower than in the classical Alzheimer-type cases. Two of the Lewy body cases with extremely low cholinergic activity were responders in therapeutic trials of the cholinesterase inhibitor, tacrine, and the combined data suggest that cholinergic therapy may be particularly relevant to patients with Lewy body type dementia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018843     DOI: 10.1097/00001756-199403000-00002

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  33 in total

Review 1.  Behavioural problems associated with dementia: the role of newer antipsychotics.

Authors:  G Stoppe; C A Brandt; J H Staedt
Journal:  Drugs Aging       Date:  1999-01       Impact factor: 3.923

Review 2.  Cholinesterase inhibitors for behavioral disturbance in dementia.

Authors:  E J Daly; W E Falk; P Brown
Journal:  Curr Psychiatry Rep       Date:  2001-06       Impact factor: 5.285

3.  Dementia with lewy bodies: diagnosis and management for primary care providers.

Authors:  Melanie Zupancic; Aman Mahajan; Kamna Handa
Journal:  Prim Care Companion CNS Disord       Date:  2011

Review 4.  Visual spatial cognition in neurodegenerative disease.

Authors:  Katherine L Possin
Journal:  Neurocase       Date:  2010-06-02       Impact factor: 0.881

5.  Differences in MR features of the substantia innominata between dementia with Lewy bodies and Alzheimer's disease.

Authors:  Haruo Hanyu; Yuriko Tanaka; Soichiro Shimizu; Hirofumi Sakurai; Toshiko Iwamoto; Kimihiko Abe
Journal:  J Neurol       Date:  2005-03-18       Impact factor: 4.849

Review 6.  Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Authors:  Michael G Erkkinen; Mee-Ohk Kim; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

7.  Clinical dementia rating performed several years prior to death predicts regional Alzheimer's neuropathology.

Authors:  Michal Schnaider Beeri; Jeremy M Silverman; James Schmeidler; Michael Wysocki; Hillel Z Grossman; Dushyant P Purohit; Daniel P Perl; Vahram Haroutunian
Journal:  Dement Geriatr Cogn Disord       Date:  2008-03-27       Impact factor: 2.959

Review 8.  The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems.

Authors:  A D Lawrence; B J Sahakian
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

9.  Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies.

Authors:  Jonathan Graff-Radford; Bradley F Boeve; Otto Pedraza; Tanis J Ferman; Scott Przybelski; Timothy G Lesnick; Prashanthi Vemuri; Matthew L Senjem; Glenn E Smith; David S Knopman; Val Lowe; Clifford R Jack; Ronald C Petersen; Kejal Kantarci
Journal:  Brain       Date:  2012-07-18       Impact factor: 13.501

10.  MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia.

Authors:  Haruo Hanyu; Tetsuichi Asano; Hirofumi Sakurai; Yuriko Tanaka; Masaru Takasaki; Kimihiko Abe
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.